The differentiation of oligodendrocyte progenitor cells (OPCs) into oligodendrocytes (OLs) promotes the remyelination in human brain. In multiple sclerosis (MS), dysfunctional OPC differentiation leads to remyelination failure and subsequent severe neurological disability.
High extracellular glutamate levels damage axons, myelin and oligodendrocytes in the context of inflammatory demyelinating disorders such as multiple sclerosis (MS).
To date, therapies for multiple sclerosis (MS) focus on modifying or suppressing the immune system rather than on remyelination. Recent findings have pointed to the κ-opioid receptor (KOR) as a therapeutic target for remyelination, but several KOR agonists have undesired side effects that limit their use. Researchers from the Victoria University of Wellington have tested KOR agonists derived from U-50488 in the preclinical setting for the management of MS.
The med-tech sector is at a turning point with great technologies, investors and buyers coming together to create a healthier ecosystem, Luc Marengère, managing partner at TVM Capital Life Science told BioWorld. As such, the venture capital firm has its eye on a new fund as it finalizes the portfolio for the current one.
Ribometrix Inc. recently discussed the discovery and preclinical evaluation of a novel potent and selective eukaryotic translation initiation factor 4E (eiF4E) inhibitor, RBX-6610, being developed for the treatment of KRAS-mutant non-small-cell lung cancer (NSCLC).
The assessment of glycosylated autoantigens as immunotolerance therapies is emerging as a potential strategy for the treatment of several autoimmune diseases, such as type 1 diabetes, Crohn’s disease or multiple sclerosis.
Breakthrough – or even better, revolutionary breakthrough – is perhaps the most overused term in drug development. But the discovery and development of GLP-1 receptor agonists (GLP-1RAs), which was honored with the 2024 Lasker-DeBakey Clinical Medical Research Award just last week, is one of the rare innovations that is deserving of the title.
At the 2024 European College of Neuropsychopharmacology (ECNP) Congress, researchers have presented work that could lead to ways to boost brain development and prevent neurodegeneration in individuals with Down syndrome.
Innovent Biologics Inc. unveiled for the first time safety and efficacy data of IBI-354, an HER2 monoclonal antibody-camptothecin derivative conjugate that shows promising efficacy signals across a range of advanced solid tumors, during the European Society of Medical Oncology (ESMO) 2024 Congress. An HER2-targeted antibody-drug conjugate developed using Innovent's topoisomerase inhibitor NT3 platform, IBI-354 combines a hydrophilic linker design with a hydrophobic payload to enhance the bystander effect, targeting adjacent antigen-low or negative tumor cells.
Chimeric antigen receptor (CAR) T-cell therapy moved the needle at the 2024 ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) congress and will continue to do so – not just in multiple sclerosis (MS), but in other autoimmune diseases as well.
RSS
